Search Results - "van der Meer, Felix"

A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon by Verhoef, Talitha I, Ragia, Georgia, de Boer, Anthonius, Barallon, Rita, Kolovou, Genovefa, Kolovou, Vana, Konstantinides, Stavros, Le Cessie, Saskia, Maltezos, Efstratios, van der Meer, Felix J.M, Redekop, William K, Remkes, Mary, Rosendaal, Frits R, van Schie, Rianne M.F, Tavridou, Anna, Tziakas, Dimitrios, Wadelius, Mia, Manolopoulos, Vangelis G, Maitland-van der Zee, Anke H

“…A genotype-guided dosing algorithm was compared with a clinical dosing algorithm in patients starting anticoagulation with acenocoumarol or phenprocoumon…”
Get full text

Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case‐cohort by Camilleri, Eleonora, Ghobreyal, Mira, Bos, Mettine H. A., Reitsma, Pieter H., Van Der Meer, Felix J. M., Swen, Jesse J., Cannegieter, Suzanne C., Rein, Nienke

“…Background Major bleeding occurs annually in 1%–3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved…”
Get full text

The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment by Kooiman, Judith, van Hagen, Nadja, Iglesias Del Sol, Antonio, Planken, Erwin V, Lip, Gregory Y H, van der Meer, Felix J M, Cannegieter, Suzanne C, Klok, Frederikus A, Huisman, Menno V

“…The HAS-BLED score enables a risk estimate of major bleeds in patients with atrial fibrillation on vitamin K-antagonists (VKA) treatment, but has not been…”
Get full text

Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism by Boon, Gudula J A M, Rein, Nienke van, Bogaard, Harm Jan, Ende-Verhaar, Yvonne M, Huisman, Menno V, Kroft, Lucia J M, Meer, Felix J M van der, Meijboom, Lilian J, Symersky, Petr, Vonk Noordegraaf, Anton, Klok, Frederikus A

“…The pathophysiology of chronic thromboembolic pulmonary hypertension (CTEPH) is not fully understood. Poor-quality anticoagulation may contribute to a higher…”
Get full text

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study by Toorop, Myrthe M. A., Rein, Nienke, Nierman, Melchior C., Vermaas, Helga W., Huisman, Menno V., Meer, Felix J. M., Cannegieter, Suzanne C., Lijfering, Willem M.

“…Background Direct oral anticoagulants (DOACs) do not require concentration monitoring. However, whether DOAC concentrations are stable and their variation…”
Get full text

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data by van Schie, Rianne M.F., Wessels, Judith A.M., le Cessie, Saskia, de Boer, Anthonius, Schalekamp, Tom, van der Meer, Felix J.M., Verhoef, Talitha I., van Meegen, Erik, Rosendaal, Frits R., Maitland-van der Zee, Anke-Hilse

“…Aims Polymorphisms in CYP2C9 and VKORC1 influence patients' phenprocoumon (PHE) and acenocoumarol (ACE) dose requirements. To provide physicians with tools to…”
Get full text

Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer by van der Hulle, Tom, MD, den Exter, Paul L., MD, van den Hoven, Pim, MD, van der Hoeven, Jacobus J., MD, PhD, van der Meer, Felix J.M., MD, PhD, Eikenboom, Jeroen, MD, PhD, Huisman, Menno V., MD, PhD, Klok, Frederikus A., MD, PhD

“…Background After diagnosis of cancer-associated VTE, guidelines recommend considering the continuation of anticoagulant treatment until the patient is cured of…”
Get full text

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists by van Rein, Nienke, Lijfering, Willem M, Bos, Mettine H A, Herruer, Martien H, Vermaas, Helga W, van der Meer, Felix J M, Reitsma, Pieter H

“…Risk scores for patients who are at high risk for major bleeding complications during treatment with vitamin K antagonists (VKAs) do not perform that well…”
Get full text

Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists by Heteren, D. Max, Lijfering, Willem M., Meer, Felix J. M., Reitsma, Pieter H., Swen, Jesse J., Bos, Mettine H. A., Rein, Nienke

Get full text

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence? by Toorop, Myrthe M. A., Chen, Qingui, Kruip, Marieke J. H. A., Meer, Felix J. M., Nierman, Melchior C., Faber, Laura, Goede, Lies, Cannegieter, Suzanne C., Lijfering, Willem M.

“…Background Non‐valvular atrial fibrillation (NVAF) patients are advised to switch from a vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) when…”
Get full text

Accuracy assessment of consecutive test strip lots for whole blood INR point-of-care instruments: clarifying the role of frozen plasma pools by van den Besselaar, Antonius M H P, Abdoel, Charmane F, van Rijn, Claudia J J, van der Meer, Felix J M, Cobbaert, Christa M

“…Background In the Netherlands, each new lot of test strips for the CoaguChek XS is validated by a group of collaborating centers. The purpose of this study was…”
Get more information

Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial by Schol‐Gelok, Suzanne, Maat, Moniek P. M., Biedermann, Joseph S., Gelder, Teun, Leebeek, Frank W. G., Lijfering, Willem M., Meer, Felix J. M., Rijken, Dingeman C., Versmissen, Jorie, Kruip, Marieke J. H. A.

“…We conducted a study to assess the effect of rosuvastatin use on fibrinolysis in patients with previous venous thromboembolism (VTE). This was a post hoc…”
Get full text

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns by Toorop, Myrthe M. A., Rein, Nienke, Nierman, Melchior C., Vermaas, Helga W., Huisman, Menno V., Meer, Felix J. M., Cannegieter, Suzanne C., Lijfering, Willem M.

“…Background Since direct oral anticoagulants (DOACs) have been introduced for treatment and prevention of thromboembolic diseases, patients on vitamin K…”
Get full text

Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study by Zielinski, Gilda D., Rein, Nienke, Teichert, Martina, Klok, Frederikus A., Rosendaal, Frits R., Meer, Felix J. M., Huisman, Menno V., Cannegieter, Suzanne C., Lijfering, Willem M.

“…Background Adherence to direct oral anticoagulants (DOACs) in patients with atrial fibrillation in every day practice may be less than in clinical trials. Aims…”
Get full text

Agreement between Coaguchek XS and STA-R Evolution (Hepato Quick) INR results depends on the level of INR by Biedermann, Joseph S, Leebeek, Frank W.G, Buhre, Peter N, de Lathouder, Sacha, Barends, Jan P.F, de Maat, Moniek P.M, van der Meer, Felix J.M, Kruip, Marieke J.H.A

“…Abstract Introduction Introducing point-of-care (POC) INR measurement to monitor anticoagulant therapy may be beneficial for both patients and anticoagulation…”
Get full text

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants by Toorop, Myrthe M.A., van Rein, Nienke, Nierman, Melchior C., Vermaas, Helga W., Huisman, Menno V., van der Meer, Felix J.M., Cannegieter, Suzanne C., Lijfering, Willem M.

“…Many patients who used vitamin K antagonists (VKAs) for long‐term prevention of thromboembolism are now actively switched to a direct oral anticoagulant…”
Get full text

Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin‐K antagonists: A randomized controlled trial by Mertens, Bram J., Kwint, Henk‐Frans, Belitser, Svetlana V., Meer, Felix J. M., Marum, Rob J., Bouvy, Marcel L.

“…Background A high number of vitamin K antagonist (VKA) users have a low proportion of time in therapeutic range (TTR) resulting in a high number of bleeding…”
Get full text

Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism by van der Hulle, Tom, Tan, Melanie, den Exter, Paul L, van Roosmalen, Mark J G, van der Meer, Felix J M, Eikenboom, Jeroen, Huisman, Menno V, Klok, Frederikus A

“…Patients with a second venous thromboembolism generally receive anticoagulant treatment indefinitely, although it is known that the recurrence risk diminishes…”
Get full text

Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands by Eckhardt, Corien L., Mauser-Bunschoten, Evelien P., Peters, Marjolein, Leebeek, Frank W. G., van der Meer, Felix J. M., Fijnvandraat, Karin

“…Summary Inhibitor development is currently the most severe complication in mild/moderate haemophilia A patients, causing increased bleeding tendency,…”
Get full text

Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy by Rombouts, Eva K., Rosendaal, Frits R., Van Der Meer, Felix J. M.

“…Summary It is unclear what advice should be given to patients using vitamin K antagonists with respect to dietary vitamin K intake. We performed a nested…”
Get full text